Creating a Sustainable Business Model for Cell and Gene Therapies

This document is a report on a roundtable discussion focused on creating a sustainable business model for cell and gene therapies, moderated by Lung-I Cheng from AmerisourceBergen. The discussion highlights the challenges faced by companies in this sector, particularly in light of recent stock-market weaknesses and regulatory hurdles. Participants included industry leaders, clinicians, and patient advocates, who addressed the importance of aligning regulatory and market access strategies. The conversation emphasized the need for a holistic approach to regulatory compliance and the significance of understanding market dynamics. Additionally, the report discusses the viability of therapies based on cost-effectiveness and the necessity for collaboration among stakeholders to identify commercially viable innovations. The document also covers supply chain challenges and the potential benefits of decentralized manufacturing in reducing costs. Ultimately, the discussion underscores the importance of multi-stakeholder engagement to ensure that therapies reach patients effectively.